Health Care Technology
Procyrion Appoints Andrew Davis As Chief Commercial Officer
Share
Seasoned MedTech executive to focus on therapy development initiatives as company continues to drive enrollment in DRAIN-HF pivotal IDE trial
HOUSTON, Dec. 2, 2025 /PRNewswire/ -- Procyrion™, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the appointment of Andrew Davis as Chief Commercial Officer, effective immediately.
In his new role, Mr. Davis will lead Procyrion's therapy development with a focus on trial enrollment, key opinion leader (KOL) engagement, podium strategy and advancing all early market development activities essential for future commercialization of the Aortix™ percutaneous mechanical circulatory support (pMCS) technology.
"Andy's deep cardiovascular experience and proven track record of launching category-creating therapies makes him an exceptional addition to the company as enrollment in our DRAIN-HF pivotal trial continues to positively progress," said Eric S. Fain, MD, President and Chief Executive Officer of Procyrion. "Patients with diuretic-resistant heart failure who have failed currently available therapies remains a significant unmet need and an underserved, large market opportunity. Andy's leadership will be instrumental as we strengthen therapy development efforts and build the foundation needed to bring the Aortix pump to patients and physicians."
Aortix is a catheter-deployed pump designed to directly increase perfusion to the kidneys while unloading the heart and improving cardiac performance. The innovative design harnesses fluid entrainment to pump blood without the need for a valve, delivering a therapeutic benefit via a physiologically natural mechanism of action for acute decompensated heart failure (ADHF) patients who remain congested despite standard medical therapy (cardiorenal syndrome or CRS).
"I'm honored to join Procyrion to advance the important work already underway," said Mr. Davis. "Patients with diuretic-resistant heart failure urgently need new options and the Aortix pump offers a compelling, new approach. I look forward to collaborating with the team and clinicians at our clinical sites to expand understanding of our therapy and to lay the groundwork in support of future commercialization."
Prior to joining Procyrion, Mr. Davis served as Chief Commercial Officer at Silk Road Medical, where he successfully spearheaded the go-to-market strategy for transcarotid artery revascularization (TCAR), a groundbreaking therapy for carotid artery disease. In addition to Silk Road, he spent 15 years at Medtronic, where he led multiple sales organizations across Cardiac and Vascular Therapies, including structural heart (TAVR), endovascular (EVAR/TEVAR), peripheral vascular, and spine/biologics. Mr. Davis has also held senior commercial roles at Endologix and 3M's Advanced Wound Therapy Group. He earned a B.S. in Political Science from Florida State University.
About Procyrion
Procyrion™, Inc. is a privately held medical device company dedicated to providing effective treatment options for patients with cardiac and renal impairment. The company is developing the Aortix™ percutaneous mechanical circulatory support device, a catheter-deployed pump technology that uniquely harnesses fluid entrainment to pump blood to address multiple conditions with significant unmet needs. Aortix is limited by Federal law to investigational use only and is not approved for sale in any geography. Please visit www.procyrion.com for more information.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not a guarantee of future performance.
View original content to download multimedia:https://www.prnewswire.com/news-releases/procyrion-appoints-andrew-davis-as-chief-commercial-officer-302629550.html
SOURCE Procyrion
Frequently Asked Questions
What is the Aortix pump?
Aortix is a catheter-deployed pump designed to increase perfusion to the kidneys, unload the heart, and improve cardiac performance in patients with acute decompensated heart failure (ADHF).
What is Procyrion's mission?
Procyrion, Inc. is a medical device company dedicated to providing effective treatment options for patients with cardiac and renal impairment.
What is Andrew Davis' role at Procyrion?
Andrew Davis is the Chief Commercial Officer. He will lead Procyrion's therapy development, focusing on trial enrollment and market development for Aortix.
First published on Tue, Dec 2, 2025
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
The Home Depot And Google Cloud Launch Agentic AI Tools To Help Customers And Associates Bring Projects From 'How-To' To 'Done'
UOG (United One Group) Wins Three Prestigious Industry Awards At CES 2026
Broadridge Invests In Deepsee, Further Harnessing Agentic AI To Transform Post-Trade Operations
NAVEE Unveils High-Performance Mobility Innovations And Expands Into Outdoor Scenarios At CES 2026
PROMISE Technology To Showcase AI-Ready Storage Infrastructure For Smart City And IVA Surveillance At Intersec Dubai 2026
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion